SISU PHARMA, INC.
EXPLOITING THE STRESS PROTECTION RESPONSE
Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology. Sisu’s first-in-class compounds demonstrate compelling efficacy in therapy-resistant cancer models where all current treatments fail. The platform provides additional opportunities to develop therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.

FOUNDERS AND SCIENTIFIC ADVISORY BOARD
Sisu Pharma is led by a team of world-class scientists with decades of experience and success in basic and translational oncology research and FDA-approved cancer drug development

Sean E. O’Brien, Ph.D.
Founder, Chief Executive Officer

Dennis J. Thiele, Ph.D.
Founder, Chief Scientific Officer, Member Scientific Advisory Board

Jiaoti Huang, M.D. Ph.D.
Founder, Chair Scientific Advisory Board
